| Budget Amount *help |
¥8,450,000 (Direct Cost: ¥6,500,000、Indirect Cost: ¥1,950,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2011: ¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000)
|
|---|
| Outline of Final Research Achievements |
We aimed to establish a new anticoagulation protocol during cardiopulmonary bypass (CPB). Our hypothesis was that administration of high-dose heparin causes massive release of tissue factor pathway inhibitor (TFPI) from endothelial cells, and antithrombin or thrombomodulin provides additional thrombin inhibition. We performed experiments using primate (Macaca fascicularis, 5kg) CPB model. Plasma TFPI was enhanced by pre-heparinization, and levels of thrombin generation were reduced through inhibition of extrinsic pathway when compared with control group. Inhibition of thrombin generation was further enhanced by the addition of antithrombin and thrombomodulin. Anti-inflammatory effects of either drug were not revealed in our anticoagulation protocol. Combined anticoagulation protocol with TFPI, antithrombin and thrombomodulin may be a promising alternative to heparin toward inhibition of both intrinsic and extrinsic pathways during CPB.
|
